Patents by Inventor Jeffrey O'Callaghan

Jeffrey O'Callaghan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR OCULAR THERAPY
    Publication number: 20220362402
    Abstract: Provided is a unit dose of recombinant adeno-associated virus (AAV) particles for expression of matrix metalloproteinase 3 (MMP-3). Further provided is a unit dose of recombinant MMP-3. Also provided are methods of use thereof, e.g., in transducing the corneal endothelium of a subject; reducing intraocular pressure in an eye of a subject; treating and/or preventing elevated intraocular pressure in a subject; and treating and/or preventing glaucoma in a subject. Subjects include primates.
    Type: Application
    Filed: October 7, 2020
    Publication date: November 17, 2022
    Inventors: Jeffrey O'CALLAGHAN, Thomas W. CHALBERG, Jr., Matthew LAWRENCE, Annahita KERAVALA, Matthew CAMPBELL, Peter HUMPHRIES
  • AAV-BASED GENE THERAPY FOR GLAUCOMA
    Publication number: 20190358305
    Abstract: The disclosure provides compositions and methods useful for treating glaucoma. In particular, the invention provides an adeno-associated viral (AAV)-mediated gene therapy for glaucoma in which transduced cells of the eye secrete a therapeutic protein (for example, a matrix metalloproteinase) resulting in remodeling of the extracellular matrix of the trabecular meshwork of said eye.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 28, 2019
    Applicant: The Provost, Fellows, Scholars and other Members of Board of Trinity College Dublin
    Inventors: Matthew Campbell, Peter Humphries, Jeffrey O'Callaghan